Tilray Brands (NASDAQ:TLRY – Free Report) had its price target reduced by Roth Mkm from $20.00 to $10.00 in a report issued on Tuesday morning,Benzinga reports. They currently have a neutral rating on the stock.
A number of other analysts have also weighed in on TLRY. Wall Street Zen raised shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a research note on Saturday, October 11th. Zacks Research cut Tilray Brands from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Tilray Brands in a research report on Wednesday, October 8th. Finally, Atb Cap Markets upgraded Tilray Brands from a “strong sell” rating to a “hold” rating in a research report on Wednesday, December 10th. One equities research analyst has rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Reduce” and a consensus price target of $13.33.
View Our Latest Report on TLRY
Tilray Brands Stock Up 5.3%
Tilray Brands (NASDAQ:TLRY – Get Free Report) last announced its quarterly earnings results on Thursday, January 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.27). The business had revenue of $217.51 million for the quarter, compared to analyst estimates of $211.15 million. Tilray Brands had a negative return on equity of 6.35% and a negative net margin of 251.69%.During the same quarter last year, the firm posted ($0.03) EPS. As a group, research analysts predict that Tilray Brands will post -0.2 earnings per share for the current year.
Institutional Investors Weigh In On Tilray Brands
Institutional investors and hedge funds have recently modified their holdings of the stock. Silverlake Wealth Management LLC purchased a new stake in shares of Tilray Brands during the third quarter valued at $25,000. Oppenheimer & Co. Inc. acquired a new stake in Tilray Brands during the 3rd quarter worth about $25,000. Unified Investment Management purchased a new stake in Tilray Brands during the third quarter valued at about $26,000. J.W. Cole Advisors Inc. boosted its holdings in shares of Tilray Brands by 203.2% in the second quarter. J.W. Cole Advisors Inc. now owns 71,890 shares of the company’s stock worth $30,000 after buying an additional 48,177 shares during the period. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of Tilray Brands in the third quarter worth approximately $30,000. 9.35% of the stock is owned by institutional investors and hedge funds.
Key Headlines Impacting Tilray Brands
Here are the key news stories impacting Tilray Brands this week:
- Positive Sentiment: Tilray announced the launch of Tilray Medical Italia, rebranding its Italian operations and expanding a EU?GMP medical cannabis portfolio via a partnership with Molteni Farmaceutici — a strategic move that strengthens Tilray’s presence in a regulated European market and could help steady medical?cannabis revenue. Tilray Medical Strengthens Italian Market Presence with the Launch of Tilray Medical Italia and Expanded Medical Cannabis Portfolio
- Positive Sentiment: SweetWater Brewing (a Tilray brand) launched Big Trip Double IPASweetWater Introduces Big Trip Double IPA: A Bold New Craft Beer
- Positive Sentiment: Insider buying activity has been reported over the past six months (including purchases by the CEO and CFO), which investors often view as a bullish signal about management’s view of the company. Tilray Medical Launches Tilray Medical Italia, Expanding Presence in Italy’s Medical Cannabis Market
- Neutral Sentiment: Tilray reported record Q2 revenue ($217.5M), showing top?line momentum in cannabis, but the report highlighted mixed results with beverage segment underperformance — a signal that revenue growth exists but profitability and segment mix remain key risks. Tilray Brands Just Posted Record Numbers for Q2. Is the Stock a Buy?
- Neutral Sentiment: Analyst price targets are highly dispersed (median ~$6; recent targets range from $2 to $10), reflecting uncertainty and mixed views that can amplify volatility as new data arrive. Tilray Medical Launches Tilray Medical Italia, Expanding Presence in Italy’s Medical Cannabis Market
- Negative Sentiment: Roth MKM and at least one other analyst recently lowered expectations, triggering a sell reaction (coverage noted shares falling ~7.4% in response) — a near?term headwind that can pressure the stock until fundamentals or guidance improve. Tilray Brands (NASDAQ:TLRY) Shares Down 7.4% on Analyst Downgrade
Tilray Brands Company Profile
Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.
Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.
Featured Stories
- Five stocks we like better than Tilray Brands
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Do not delete, read immediately
- NEW LAW: Congress Approves Setup For Digital Dollar?
- Executive Order 14330: Trump’s Biggest Yet
Receive News & Ratings for Tilray Brands Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray Brands and related companies with MarketBeat.com's FREE daily email newsletter.
